Novo Nordisk, FDA

Drug compounders sue FDA over Novo Nordisk’s Ozempic, Wegovy
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug Wegovy and diabetes treatment Ozempic without a fight. An industry group has sued the U.
Novo Nordisk’s Wegovy, Ozempic No Longer in Short Supply, According to FDA
The Food and Drug Administration has determined that the shortage of Wegovy® (semaglutide) and Ozempic® (semaglutide) is resolved.
Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months.
Novo Nordisk shortage of Ozempic and Wegovy ends, threatening compounders
The FDA has declared an end to the shortage of Novo Nordisk’s blockbuster drug semaglutide, threatening the ability for compounding pharmacies to make copies of Ozempic and Wegovy.
FDA announces end to Wegovy and Ozempic drug shortages, but it could mean higher prices
The FDA has announced that the shortage of Wegovy and Ozempic, medications used for weight loss and diabetes management, is over.
Drug compounders sue US FDA over removal of Wegovy, Ozempic from shortage list
Drug compounders sued the U.S. Food and Drug Administration on Monday over its decision last week to remove Novo Nordisk's weight-loss and diabetes treatments Wegovy and Ozempic from its shortage list,
Drug compounders sue FDA over declaration ending Wegovy shortage
Telehealth provider Hims & Hers said it will tell consumers they need to seek “alternative options on the commercial dosing,” but in earnings Monday still forecast higher revenue and profits in 2025.
Drug compounders sue FDA over semaglutide status: report
Makers of copycat versions of Novo Nordisk's (NVO) popular weight-loss drug semaglutide, also known as Ozempic and Wegovy, are suing the FDA for removing the GLP-1 medication from its shortage list. The Outsourcing Facilities Association,
Novo Nordisk shares are rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...
Novo’s Ozempic Shortage Is Declared Over, Hitting Copycats
Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s ...
Novo Nordisk Stock Rallies on Weight-Loss Retreat by Hims & Hers
Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...
Becker's Hospital Review2d
FDA sets deadline to end sales of Ozempic, Wegovy copycats
Semaglutide — the key ingredient in Ozempic and Wegovy — had been in shortage since 2022. Now that supply has stabilized, state-licensed compounding pharmacies and physicians must stop selling ...
Why Novo Nordisk Stock Keeps Going Down
Novo Nordisk ( NVO -1.22%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...
Why Novo Nordisk Is A Strong Buy Despite Market Concerns
Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...
In China you can get Ozempic and Wegovy within the hour for just $100 a month
Delivery apps are allowing Chinese citizens to get their hands on the popular weight-loss and diabetes drugs at the touch of ...
Why Novo Nordisk Stock Popped on Friday
Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ...